Reflections on reactions to the [Nuffield] Council’s report on NIPT
By Catherine Joynson,
Nuffield Blog
| 03. 09. 2017
The Nuffield Council on Bioethics’ report on non-invasive prenatal testing (NIPT) was published last week, with a launch event in the House of Commons. The event itself was full of emotion, reflecting the real and important impact that NIPT and prenatal testing can have on people’s lives. The report has also elicited a number of other reactions. Having spent the last 12 months or so talking to a wide range of people and organisations with an interest in NIPT, this does not surprise me. As we didn’t have time to answer every question at the event, this article attempts to continue the conversation, respond to some of the specific comments that have been aired, and describe how we came to our conclusions and recommendations.
Too restrictive or too permissive?
Some groups have commented that our conclusions are too restrictive, particularly in relation to our recommendation that NIPT should only be used to test for significant medical conditions or impairments (with some exceptions). Others believe that they are too permissive, for example that we have missed the opportunity to support campaigns to...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...
By Isabel van Brugen, Newsweek | 06.05.2025
A U.S.-based biotech company has unveiled a new in vitro fertilization (IVF) option that allows parents to select embryos based on genetic markers tied to health and longevity.
DNA testing and analysis company Nucleus Genomics has announced the world's first...
By Jonathan D. Grinstein, PhD, Inside Precision Medicine | 06.03.2025
On Tuesday, 307 days after he was first admitted to Children’s Hospital of Philadelphia (CHOP), KJ Muldoon went home after being successfully treated with the first personalized CRISPR gene editing therapy. KJ, who was born with a serious and...